Shilpa Pharma Lifesciences Ltd's Unit 2, Raichur, Karnataka has cleared the COFEPRIS-Mexico GMP Inspection

Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited's Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has undergone a GMP inspection by COFEPRIS-Mexico from November 6-10, 2023.

Following a successful inspection, the Unit has been issued GMP Certification from COFEPRIS-Mexico.

The facility is involved in manufacturing various oncology and nononcology APIs. The company remains commit ted to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 643.65 as compared to the previous close of Rs. 643.75. The total number of shares traded during the day was 22563 in over 1996 trades.

The stock hit an intraday high of Rs. 674.55 and intraday low of 627.85. The net turnover during the day was Rs. 14650772.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 ShilpaPharmaLifesciences API ManufacturingFacility Unit2 GMPInspection COFEPRIS Mexico